Biovie Inc. (BIVI): Total Liabilities
$3.98M
As of 2026-06-30
-41.4%
3-year compound annual growth
+31.9%
5-year compound annual growth
+17.4%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $3.98M | +56.1% | 2026-08-13, Balance as of period end |
| 2025-06-30 | $2.55M | -73.7% | 2026-08-13, Balance as of period end |
| 2024-06-30 | $9.70M | -50.9% | 2025-08-15, Balance as of period end |
| 2023-06-30 | $19.76M | +20.2% | 2024-09-30, Balance as of period end |
| 2022-06-30 | $16.44M | n/m | 2023-08-16, Balance as of period end |
| 2021-06-30 | $996.4K | -95.8% | 2022-09-27, Balance as of period end |
| 2020-06-30 | $23.58M | n/m | 2021-08-30, Balance as of period end |
| 2019-06-30 | $443.5K | -78.5% | 2020-08-07, Balance as of period end |
| 2018-06-30 | $2.06M | +71.0% | 2019-09-27, Balance as of period end |
| 2017-06-30 | $1.21M | +50.3% | 2018-10-05, Balance as of period end |
| 2016-06-30 | $803.2K | n/a | 2017-08-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Biovie Inc. (BIVI) | 2026-06-30 | $3.98M | +56.1% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $10.12M | +22.1% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $6.11M | -33.7% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $123.69M | +8.4% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $1.48M | -56.9% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $20.23M | +275.8% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $5.06M | -48.4% |
| Cingulate Inc. (CING) | 2025-12-31 | $12.56M | +69.6% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
Compare BIVI, XCUR, ACTU, CYDY side by side · Screen every company in Pharmaceutical Preparations ↗